Recombinant Human KNG1 (C-6His)

Description

EnkiLife provides the Recombinant Human KNG1 (C-6His) protein,aslo know as Kininogen-1,lpha-2-Thiol Proteinase Inhibitor,Fitzgerald Factor,High Molecular Weight Kininogen,HMWK,Williams-Fitzgerald-Flaujeac Factor,KNG1,BDK,KNG, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Kininogen-1 is produced by our Mammalian expression system and the target gene encoding Gln19-Ser427 is expressed with a 6His tag at the C-terminus.Accession:P01042-2. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:46.89 KDa. Background:Kininogen-1 is a secreted protein which contains three cystatin domains. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms. Kininogen-1 plays a critical role in blood coagulation and inflammatory response. Kininogens are inhibitors of thiol proteases. Kininogen-1 participates in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, also inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. The active peptide bradykinin that is released from Kininogen-1 shows a variety of physiological effects: influence in smooth muscle contraction, induction of hypotension, natriuresis and diuresis, decrease in blood glucose level. It is a mediator of inflammation and causes increase in vascular permeability, stimulation of nociceptors release of other mediators of inflammation. It has a cardioprotective effect. LMW-kininogen inhibits the aggregation of thrombocytes and doesn’t involved in blood clotting.